论文部分内容阅读
年龄相关性黄斑变性(AMD)是50岁以上老年人致盲的首要原因,随着人口老龄化,AMD的患病率也在升高,其中湿性AMD以脉络膜新生血管(CNV)形成为特征,血管内皮生长因子(VEGF)过度分泌为其主要机制,最终可致视力减退或盲,是90％以上AMD患者视力损害的主要原因.针对新生血管生成的靶向VEGF药物,如雷珠单抗、阿柏西普等的应用大大降低了患者的致盲率,是湿性AMD的一线治疗药物.但仍存在部分患者对治疗无反应或长期治疗后视力不能维持,频繁注射也增加了并发症的风险和经济负担.为了进一步改善湿性AMD患者的生存质量和长期预后,多种新的治疗方式已经或即将迈入临床,包括通过相同或不同靶点联合治疗以增进疗效、改变或简化用药方式、抑制VEGF受体酪氨酸蛋白激酶等.本文就治疗湿性AMD的抗VEGF药物研究进展做一简要综述.“,”Age-related macular degeneration (AMD) is the primary cause of the blindness among the population aged more than 50 years old.The prevalence of AMD increases with age growing.Wet AMD is the main cause of the visual impairment in over 90％ of AMD patients,which is characterized by formation of choroidal neovascularization.It takes the hypersecretion of vascular endothelial growth factor (VEGF) as a mechanism,leading to vision loss and blindness finally.Targeted anti-VEGF therapy for angiogensis,like ranibizumab and aflibercept can reduce the rate of blindness greatly in AMD patients.It has become the front-line therapy in clinical.However,there still exist some problems.Some patients do not respond to the treatment or their eyesight cannot sustain after long-term treatment.In addition,repeated injection increases the risk of complications and economic burden.In order to further increase their quality of life and improve long-term outcome in patients with wet AMD,a steady flow of new therapy has emerged,such as function towards the same or different targets of antiangiogenesis to enhance the effect by combination therapy,improving or simplifying the mode of administration,inhibiting VEGFR tyrosine protein kinase,etc.This paper reviewed the research progress of anti-VEGF for the therapy in wet AMD.